Veriheal Expands Patient Support Services With State-Compliant Medical Cannabis Letters
DENVER — Veriheal, a leading health-tech company specializing in personalized cannabis access, announced this month the expansion of its services to include support beyond certification. The new offerings include state-compliant, physician-signed letters that provide documentation of lawful cannabis use by medical marijuana patients.
Article content
Veriheal's expanded suite includes medical cannabis letters of necessity and medical diagnosis summaries that confirm lawful marijuana use. These documents are designed to support patients through legal hurdles and assist with applications for employment, insurance, and public programs such as social services.
Article content
Article content
This launch is the first in a series of services reflecting Veriheal's commitment to holistic patient support. The physician-signed letters aim to help patients confidently navigate complex systems while remaining compliant with both federal and state laws. Veriheal will continue the rollout later this year, addressing challenges of medical cannabis use that extend beyond card certification.
Article content
'Our patients deserve peace of mind when managing their health,' said Erik Smith, M.D., Medical Director at Veriheal. 'This launch is a foundational step in Veriheal's evolution from a certification provider to a long-term partner in wellness and advocacy.'
Article content
Available now, patients can request letters to verify legal cannabis use for:
Article content
Each letter is signed by a licensed physician based on the patient's active medical cannabis certification. Patients without a medical cannabis card can access a bundled service to obtain certification and letters of medical necessity.
Article content
The letters are available digitally on Veriheal's platform and can be requested directly from patients' user portal. For more information, visit veriheal.com/services.
Article content
About Veriheal
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact:
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Risk of radioactive contamination prompts Walmart frozen shrimp recall in U.S.
Walmart has recalled frozen, raw shrimp sold in 13 U.S. states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia. The products could pose a "potential health concern" for people exposed to low levels of Cesium-137 over time, FDA officials said. "If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away," FDA officials said in a statement. The risk from the recalled shrimp is "quite low," said Donald Schaffner, a food safety expert at Rutgers University. Cesium-137 is a byproduct of nuclear reactions, including nuclear bombs, testing, reactor operations and accidents. It's widespread around the world, with trace amounts found in the environment, including soil, food and air. The level detected in the frozen breaded shrimp was far lower than FDA intervention levels. However, the agency said that avoiding potentially contaminated products could reduce exposure to low-level radiation that could lead to health problems over time. The FDA is investigating reports of Cesium-137 contamination in shipping containers and products processed by P.T. Bahari Makmur Sejati, doing business as BMS Foods of Indonesia. U.S. Customs and Border Protection officials alerted FDA that they found Cesium-137 in shipping containers sent to U.S. ports in Los Angeles, Houston, Miami and Savannah, Georgia. FDA officials collected several product samples and detected contamination in one sample of frozen breaded shrimp. The shipping containers and products were denied entry into the U.S. However, the FDA then learned that Walmart had received potentially affected products imported after the first detection, from shipments that did not trigger contamination alerts. Walmart immediately recalled the products, a company spokesperson said. They include Great Value brand frozen raw shrimp with lot codes 8005540-1, 8005538-1 and 8005539-1, all with best-by dates of March 15, 2027. The shrimp was sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Consumers should discard the products or return them to any Walmart store for refund.
CTV News
an hour ago
- CTV News
Walmart recalls frozen shrimp in U.S. over potential radioactive contamination
Walmart has recalled frozen, raw shrimp sold in 13 states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia. ADVERTISEMENT The products could pose a 'potential health concern' for people exposed to low levels of Cesium-137 over time, FDA officials said. 'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away,' FDA officials said in a statement. The risk from the recalled shrimp is 'quite low,' said Donald Schaffner, a food safety expert at Rutgers University. Cesium-137 is a byproduct of nuclear reactions, including nuclear bombs, testing, reactor operations and accidents. It's widespread around the world, with trace amounts found in the environment, including soil, food and air. The level detected in the frozen breaded shrimp was far lower than FDA intervention levels. However, the agency said that avoiding potentially contaminated products could reduce exposure to low-level radiation that could lead to health problems over time. The FDA is investigating reports of Cesium-137 contamination in shipping containers and products processed by P.T. Bahari Makmur Sejati, doing business as BMS Foods of Indonesia. U.S. Customs and Border Protection officials alerted FDA that they found Cesium-137 in shipping containers sent to U.S. ports in Los Angeles, Houston, Miami and Savannah, Georgia. FDA officials collected several product samples and detected contamination in one sample of frozen breaded shrimp. The shipping containers and products were denied entry into the U.S. However, the FDA then learned that Walmart had received potentially affected products imported after the first detection, from shipments that did not trigger contamination alerts. Walmart immediately recalled the products, a company spokesperson said. They include Great Value brand frozen raw shrimp with lot codes 8005540-1, 8005538-1 and 8005539-1, all with best-by dates of March 15, 2027. The shrimp was sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Consumers should discard the products or return them to any Walmart store for refund. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Jonel Aleccia, The Associated Press
National Post
2 hours ago
- National Post
Curewell Capital Closes Oversubscribed Inaugural Fund at $535 Million
Article content LOS ANGELES — Curewell Capital ('Curewell'), a private equity firm focused on building industry-leading middle-market healthcare companies, announced the closing of Curewell Capital I, LP (together with its related vehicles, the 'Fund') at its hard cap of $535 million. The inaugural Fund was raised in a single closing and completed less than five months after launch. Article content Curewell secured commitments from a diverse group of global institutional investors, comprised of leading endowments, foundations, pensions, insurance companies, consultants, family offices, and industry executives. Article content Curewell is led by Michael Dal Bello and Ceron Rhee, who have worked together for nearly two decades, including their shared tenures at Blackstone and more recently at Pritzker Private Capital, where they led the healthcare investment practice. The Fund builds on the team's established strategy of acquiring leading U.S. healthcare businesses across healthcare services, pharmaceutical services, medical devices, and healthcare technology. Curewell seeks to partner with experienced founders and management teams leading extraordinary healthcare companies to help accelerate growth and operational performance. Article content 'We are grateful for the trust and support of an exceptional group of investors. We are further honored to work with founders, owners, and management teams who share our vision of increasing access to healthcare, lowering overall system costs, and enhancing quality of care. We look forward to building lasting value together,' said Michael Dal Bello, Co-Founder and Partner. 'This fund represents our next chapter in partnering with accomplished teams advancing innovation and transformation in healthcare,' added Ceron Rhee, Co-Founder and Partner. 'We are seeing strong secular tailwinds across our key areas of focus, providing meaningful opportunities for companies to improve outcomes and drive efficiencies throughout the U.S. healthcare system.' Article content Probitas Partners acted as the exclusive placement advisor for the Fund, and Kirkland & Ellis LLP acted as fund counsel. Article content About Curewell Capital Article content Curewell is a Los Angeles–based private equity firm focused on building industry-leading middle-market healthcare companies headquartered in North America. Drawing upon decades of investment and operating experience across healthcare services, pharmaceutical services, medical devices, and healthcare technology, Curewell seeks to partner with founders and management teams leading premier companies that improve patient outcomes, create efficiencies, and foster innovation. Curewell's proprietary GRO™ framework is tailored to each company to drive long-term value through growth and operational excellence. For additional information, please visit Article content Article content Article content Article content
